NCT02181088

A Phase Ia Clinical Trial to Assess the Safety and Immunogenicity of New Plasmodium Falciparum Malaria Vaccine Candidates ChAd63 RH5 Alone and With MVA RH5

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 26 (actual)
• Sponsor: University of Oxford · Academic / Other
• Sex: All
• Age: 18 Years – 50 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to assess two new malaria vaccines, ChAd63 RH5 and MVA RH5, at different doses and alone or in combination. The study will enable us to assess the safety of the vaccines and the extent of the immune response in healthy volunteers. We will do this by giving volunteers one or two vaccinations, doing blood tests and collecting information about any symptoms that occur after vaccination. This is the first trial to use these vaccines in humans.

Conditions

• Malaria
• Plasmodium Falciparum

Interventions

Type	Name	Description
BIOLOGICAL	ChAd63 RH5 low dose	ChAd63 RH5 at 5 x 10\^9 vp
BIOLOGICAL	ChAd63 RH5 full dose	ChAd63 RH5 at 5 x 10\^10 vp
BIOLOGICAL	MVA RH5 low dose	MVA RH5 at 1 x 10\^8 pfu
BIOLOGICAL	MVA RH5 full dose	MVA RH5 at 2 x 10\^8 pfu

Timeline

• Start date: 2014-08-01
• Primary completion: 2015-10-01
• Completion: 2015-10-01
• First posted: 2014-07-03
• Last updated: 2015-12-03

Locations

2 sites across 1 country: United Kingdom